Hospitals held a 55.44% share of the enzymatic wound debridement market in 2025, reflecting their central role in managing patients with complex wounds that require supervised treatment, infection control, and coordinated clinical assessment. Hospital settings remain the leading end-use segment because enzymatic wound debridement is often used where wound severity, comorbidities, and healing progress need close monitoring by multidisciplinary care teams. This care environment also supports consistent product use in cases where treatment decisions must be integrated with broader surgical, vascular, or diabetes-related wound management.

Homecare is emerging as the fastest-growing end-use segment in the enzymatic wound debridement market as wound treatment increasingly shifts toward lower-acuity, longer-duration care outside institutional settings. Its momentum is reinforced through the practical need to manage chronic and recovering wounds in a more convenient setting while reducing repeated hospital visits. Compared with hospitals, homecare gains traction where patients and caregivers can continue prescribed enzymatic wound debridement over extended periods, making it well aligned with the broader move toward decentralized wound management.

Type Segment Analysis: Chronic Wounds (Largest Segment) vs Acute Wounds (Fastest-Growing Segment)

Within the enzymatic wound debridement market, chronic wounds accounted for the largest share in 2025 because these cases typically require prolonged management and repeated debridement as part of ongoing healing support. The segment’s leadership is underpinned by the persistent clinical burden of wounds that do not progress through normal healing timelines, creating steady demand for selective debridement approaches that can be used when regular tissue management is needed. This makes chronic wounds the core application area for enzymatic wound debridement in routine practice.

Acute wounds represent the fastest-growing type segment in the enzymatic wound debridement market, driven by expanding use in situations where timely removal of non-viable tissue can support faster recovery and reduce complications during early wound care. Growth is stronger than in chronic wounds because acute wound management is increasingly focused on efficient intervention at earlier stages, especially where clinicians seek targeted debridement without relying solely on more invasive approaches. That practical shift is helping acute wounds gain momentum as treatment pathways broaden.